公开(公告)号：US6043233A

公开(公告)日：2000-03-28

申请号：US235804

申请日：1999-01-22

申请人： David S. Garvey ,  L. Gordon Letts ,  H. Burt Renfroe ,  Sang William Tam

发明人： David S. Garvey ,  L. Gordon Letts ,  H. Burt Renfroe ,  Sang William Tam

IPC分类号： C07D417/04 ,  A61K31/00 ,  A61K31/19 ,  A61K31/403 ,  A61K31/404 ,  A61K31/405 ,  A61K31/54 ,  A61K31/541 ,  A61K38/00 ,  A61K45/00 ,  A61P1/00 ,  A61P1/04 ,  A61P29/00 ,  A61P43/00 ,  C07C203/00 ,  C07C327/28 ,  C07C381/00 ,  C07D209/28 ,  C07D417/12 ,  C07J41/00 ,  C07K5/02 ,  A61K31/192 ,  A61K31/407 ,  A61K31/60 ,  A61K31/603 ,  A61K31/606

CPC分类号： C07D417/12 ,  A61K31/343 ,  A61K31/60 ,  C07C203/00 ,  C07C327/28 ,  C07C381/00 ,  C07D209/28 ,  C07J41/0055 ,  C07K5/0215 ,  A61K38/00

摘要： Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.

摘要翻译： 已被一氧化氮基团取代的非甾体抗炎药; 组合物，其包含（i）非甾体抗炎药，其可以任选地被一氧化氮基团取代，和（ii）直接捐赠，转移或释放一氧化氮基团（优选作为带电物质，特别是亚硝基鎓）的化合物; 并且公开了使用所述组合物治疗炎症，疼痛，胃肠道损伤和/或发烧的方法。所述化合物和组合物可防止否则由非甾体抗炎药引起的胃肠道，肾脏和其它毒性。

公开(公告)号：US5476667A

公开(公告)日：1995-12-19

申请号：US39175

申请日：1993-04-16

申请人： Arne Kristensen ,  Per Holm

发明人： Arne Kristensen ,  Per Holm

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K31/43 ,  A61K31/606 ,  A61K31/616 ,  A61K31/655 ,  A61K47/34

CPC分类号： A61K9/1641 ,  A61K9/1694

摘要： A melt granulating method for the production of pellets (spheres) which contain a therapeutically active substance of high-dosage type. The method is characterized by: (i) mechanically working a mixture which contains (a) the active substance in cohesive form and (b) a binder (melting point 40.degree. C.-100.degree. C.) while supplying sufficient energy for the binder to melt and to form spherical overwetted pellets; (ii) adding further cohesive substance, while maintaining the mechanical working; (iii) interrupting the mechanical working and supply of energy and cohesive substance when the desired mean particle size of dry pellets (spheres) has been achieved; and (iv) removing the smallest and largest particles and dividing the remaining pellets into dosage batches. A novel pharmaceutical composition containing a dosage of 300-500 mg of pellets is obtainable from this process.

摘要翻译： PCT No.PCT / SE91 / 00690 Sec。 371日期：1993年04月16日 102（e）日期1993年4月16日PCT 1991年10月15日PCT PCT。 公开号WO92 / 06679 日期：1992年4月30日。一种用于生产含有高剂量治疗活性物质的丸粒（球）的熔体造粒方法。 该方法的特征在于：（i）机械加工包含（a）活性物质以粘结形式和（b）粘合剂（熔点为40℃-100℃）的混合物，同时为粘合剂提供足够的能量 熔化并形成球形过湿颗粒; （ii）在保持机械加工的同时加入更多的粘性物质; （iii）当达到所需的干颗粒（球体）平均颗粒尺寸时，中断机械加工和能量供应和粘性物质; 和（iv）除去最小和最大的颗粒，并将剩余的颗粒分成剂量批料。 从该方法可获得含有300-500mg粒料剂量的新型药物组合物。

公开(公告)号：US20240066010A1

公开(公告)日：2024-02-29

申请号：US18117899

申请日：2023-03-06

申请人： Salix Pharmaceuticals, Ltd.

发明人： William Forbes

IPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

CPC分类号： A61K31/437 ,  A61K31/08 ,  A61K31/352 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/606 ,  A61K31/7016 ,  A61K31/785 ,  A61K38/14 ,  A61K38/31 ,  A61K45/06

摘要： The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

公开(公告)号：US20230293553A1

公开(公告)日：2023-09-21

申请号：US18014867

申请日：2021-07-06

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Song Li ,  Yixian Huang ,  Haozhe Huang

IPC分类号： A61K31/606 ,  A61K31/704 ,  A61K47/34 ,  A61K9/107

CPC分类号： A61K31/606 ,  A61K31/704 ,  A61K47/34 ,  A61K9/1075

摘要： A polymer includes a hydrophobic polymer backbone, a first plurality of pendant groups attached to the hydrophobic polymer backbone and including a first moiety including at least one group selected for ionic interaction with a second therapeutic agent, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one hydrophilic polymer. The first moiety is attached via a labile bond and is released in vivo from the polymer to provide a biologically or therapeutically active form of a first therapeutic compounds.

公开(公告)号：US11738032B2

公开(公告)日：2023-08-29

申请号：US17094233

申请日：2020-11-10

申请人： Dr. Falk Pharma GmbH

发明人： Rudolph Wilhelm ,  Markus Pröls ,  Roland Greinwald ,  Ralf Mohrbacher

IPC分类号： A01N37/00 ,  A61K31/215 ,  A01N37/12 ,  A01N37/44 ,  A61K31/24 ,  A01N25/00 ,  A61K31/58 ,  A61K9/02 ,  A61K31/606 ,  A61P29/00

CPC分类号： A61K31/58 ,  A61K9/02 ,  A61K31/606 ,  A61P29/00 ,  A61K31/58 ,  A61K2300/00 ,  A61K31/606 ,  A61K2300/00

摘要： Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

公开(公告)号：US11672803B2

公开(公告)日：2023-06-13

申请号：US16926280

申请日：2020-07-10

申请人： Pharmacyclics LLC

发明人： Joseph J. Buggy

IPC分类号： A61K31/519 ,  A61K31/195 ,  A61K31/436 ,  A61K31/454 ,  A61K31/475 ,  A61K31/573 ,  A61K31/606 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7076 ,  A61K45/06 ,  A61K9/48 ,  A61K47/12 ,  A61K47/10 ,  A61K9/00 ,  A61K47/20 ,  A61K47/36 ,  A61K47/14 ,  A61K47/38 ,  A61K47/26 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/7032 ,  A61K39/395 ,  C07D487/04 ,  A61K31/337 ,  A61K31/437 ,  A61K31/664 ,  A61K9/06

CPC分类号： A61K31/519 ,  A61K9/007 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0048 ,  A61K9/0056 ,  A61K9/0078 ,  A61K9/06 ,  A61K9/4866 ,  A61K31/195 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/437 ,  A61K31/454 ,  A61K31/475 ,  A61K31/4745 ,  A61K31/573 ,  A61K31/606 ,  A61K31/664 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7032 ,  A61K31/7076 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39533 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  C07D487/04 ,  A61K31/195 ,  A61K2300/00 ,  A61K31/436 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00 ,  A61K31/475 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/606 ,  A61K2300/00 ,  A61K31/675 ,  A61K2300/00 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/7076 ,  A61K2300/00

摘要： Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：US20230149481A1

公开(公告)日：2023-05-18

申请号：US17907715

申请日：2021-03-31

申请人： Servatus Ltd

发明人： Wanye FINLAYSON

IPC分类号： A61K35/747 ,  A61K31/606 ,  A61K38/13 ,  A61K39/395 ,  C07K16/24 ,  A61K31/519 ,  A61P1/00 ,  A61P37/06

CPC分类号： A61K35/747 ,  A61K31/606 ,  A61K38/13 ,  A61K39/3955 ,  C07K16/241 ,  A61K31/519 ,  A61P1/00 ,  A61P37/06 ,  A61K2039/505

摘要： Methods for treating an inflammatory bowel disease or at least one symptom thereof, comprising administering to a subject in need thereof an effective amount of: a compound selected from an immunosuppressant and an aminosalicylate; and one or more Lactobacillus species selected from Lactobacillus buchneri, Lactobacillus paracasei, Lactobacillus zeae, Lactobacillus rapi, Lactobacillus parafarraginis, and Lactobacillus diolivorans, and/or a culture supernatant or cell free culture filtrate derived from culture media in which said one or more Lactobacillus species has been cultured.

公开(公告)号：US11491118B2

公开(公告)日：2022-11-08

申请号：US17394710

申请日：2021-08-05

申请人： TWEED INC.

发明人： Mark Andrew Hetherington ,  Chris Schnarr

IPC分类号： A61K36/00 ,  A61K31/05 ,  A61K9/00 ,  A61K31/196 ,  A61K36/28 ,  A61K31/192 ,  A61K36/61 ,  A61K31/165 ,  A61K31/606

摘要： The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject.

公开(公告)号：US11464745B2

公开(公告)日：2022-10-11

申请号：US16463728

申请日：2017-11-27

申请人： UCL Business PLC

发明人： Abdul Basit ,  Alvaro Goyanes ,  Simon Gaisford ,  Fabrizio Fina

IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K9/16 ,  A61K9/70 ,  A61K31/167 ,  A61K31/606 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y70/00 ,  B33Y80/00

摘要： A process for producing a solid pharmaceutical dosage formulation, said process comprising powder bed fusion selective laser 3-dimensional printing of a mixture comprising: (a)a drug; and (b)an excipient; whereinat least one of said drug and said excipient absorbs electromagnetic radiation at a wavelength emitted by the laser; or (a)a drug; (b)an excipient; and (c)an absorbent material which absorbs electromagnetic radiation at a wavelength emitted by the laser.

公开(公告)号：US20220175785A1

公开(公告)日：2022-06-09

申请号：US17676032

申请日：2022-02-18

申请人： Pharmacyclics LLC

发明人： Joseph J. Buggy ,  Gwen Fyfe ,  Laurence Elias ,  David J. Loury

IPC分类号： A61K31/519 ,  A61K31/195 ,  A61K31/436 ,  A61K31/454 ,  A61K31/475 ,  A61K31/573 ,  A61K31/606 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7076 ,  A61K45/06 ,  A61K9/48 ,  A61K47/12 ,  A61K47/10 ,  A61K9/00 ,  A61K47/20 ,  A61K47/36 ,  A61K47/14 ,  A61K47/38 ,  A61K47/26 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/7032 ,  A61K39/395 ,  C07D487/04 ,  A61K31/337 ,  A61K31/437 ,  A61K31/664 ,  A61K9/06

摘要： Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.